Medicare Anti-VEGF Evaluation: TA Notes Safety Comparison Challenges For Avastin, Cost-Benefit Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The Institute for Clinical and Economic Review conducted a technology assessment for anti-VEGF agents in diabetic macular edema for CMS in preparation for an upcoming MedCAC review.
You may also be interested in...
Drug Pricing Critic Peter Bach Named Chair Of Medicare Advisory Panel
But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.
Avastin, Lucentis Assumed Comparable In DME Absent More Data, MEDCAC Members Say
In a vote, the panel expressed little confidence in the adequacy of the available evidence on whether there are clinically meaningful differences in outcomes among the anti-VEGF agents.
MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012
Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.